Small molecule · Inhibitor of c-MET (hepatocyte growth factor receptor) (MET), VEGFR2 (KDR) (KDR) and Axl receptor tyrosine kinase (AXL) · developed by Sunshine Lake Pharma Co.
Ningetinib is an orally available small-molecule inhibitor of the receptor tyrosine kinases c-MET, VEGFR2, Axl, Mer and Flt3, binding these kinases and blocking their signaling. It is being studied in advanced non-small cell lung cancer (NSCLC).
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.